Eli Lilly reported a 38.6% year-over-year revenue increase to $24.4 billion in Q3, driven by strong sales of its diabetes and obesity treatments Mounjaro and Zepbound, which generated $16.08 billion, up 59.1% from last year. Sales of Ebglyss, a treatment for atopic dermatitis, also rose 59.1% year-over-year to $202 million. These results highlight Eli Lilly's growing strength in endocrine and metabolic disease markets, supporting continued investor confidence in the company's growth prospects.
Eli Lilly shares trade at USD 1,369.73 on Pluang as of Oct 30, 2026, showing a strong 6.28% gain in one day. The stock's market cap stands at $1.15 trillion, reflecting robust investor interest. Buyers dominate with 71% of order activity, supporting the company's growth narrative.
Eli Lilly's stock surged 6% to a record $1.3 trillion valuation after reporting stronger-than-expected earnings driven by sales of weight-loss drugs Mounjaro and Zepbound. Both drugs exceeded sales expectations by over 5%, reinforcing Eli Lilly's dom...
Merck's stock rose 5% following its Q3 2026 earnings report, which beat analyst expectations with adjusted EPS of $2.49 and revenue of $18.09 billion. The company raised its 2026 adjusted EPS guidance to $2.77-$2.82, driven by strong sales of its can...
Eli Lilly reported a record quarter driven by strong sales of its weight-loss injection, Zepbound. The company raised its 2026 revenue outlook for the third time this year, now expecting between $91 billion and $92 billion. This reflects the growing ...
Eli Lilly reported a 39% revenue increase to $24.4 billion in Q3 2026, led by strong sales of Mounjaro and Zepbound. Earnings per share rose 16% to $7.22 on a reported basis, with the company raising its full-year revenue guidance to $91-$92 billion....
Eli Lilly will report its third-quarter earnings and revenue, expected to be boosted by strong sales of its obesity drug Zepbound and diabetes treatment Mounjaro. Investors are also watching the performance of Foundayo, an obesity pill launched in Ap...
